Aquestive Therapeutics Inc. (AQST) Reports In-Line Q3 EPS

Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q3 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $12.81 million versus the consensus estimate of $12.7 million.

For earnings history and earnings-related data on Aquestive Therapeutics Inc. (AQST) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Pyxis Oncology, Inc. (PYXS) Misses Q2 EPS by 4c
• Arcos Dorados (ARCO) Tops Q2 EPS by 7c